Sunitinib induces macrophage dysfunction and impaired tissue regeneration through suppression of PPARγ. [PDF]
Zhang Z +9 more
europepmc +1 more source
Sunitinib-Induced Hand-Foot Skin Reaction: A Case Report. [PDF]
Patel A, Sanghvi R.
europepmc +1 more source
P4HA3-mediated hydroxylation of SLC7A11 drives tyrosine kinase inhibitor resistance by suppressing ferroptosis in clear cell renal cell carcinoma. [PDF]
Chen Y +13 more
europepmc +1 more source
Expression of ABCB1, ABCB5, and ABCG2 Transporters in Human Renal Cell Carcinoma and Their Underlying Signaling Pathways. [PDF]
Vass A +9 more
europepmc +1 more source
1-Butylindoline-2,3-dione derivatives as potent VEGFR-2 inhibitors: synthesis, mechanistic anticancer studies, and molecular dynamics simulations. [PDF]
El-Naggar M +9 more
europepmc +1 more source
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma. [PDF]
Kanesvaran R +27 more
europepmc +1 more source
Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States. [PDF]
Yan C +5 more
europepmc +1 more source
Development and Validation of an LC-MS/MS Method for Simultaneous Quantification of Pazopanib, Cabozantinib, Sorafenib, Axitinib, Tivozanib, Sunitinib, and the Metabolites Sorafenib N-Oxide and Desethyl-Sunitinib in Human Plasma. [PDF]
Greibe E +3 more
europepmc +1 more source
Renal squamous cell carcinoma postoperative recurrence treated with sunitinib combined with radiotherapy: a case report. [PDF]
Du L, Wang L.
europepmc +1 more source
Anti-angiogenic therapy in thymic carcinoma: a narrative review of current evidence and emerging combinations. [PDF]
Kim HS, Padda SK.
europepmc +1 more source

